STAVUDINE
Clinical safety rating: safe
Animal studies have demonstrated safety
Nucleoside reverse transcriptase inhibitor; intracellularly phosphorylated to active triphosphate which competitively inhibits HIV-1 reverse transcriptase and causes DNA chain termination.
| Metabolism | Stavudine is not significantly metabolized; approximately 40% of the dose is excreted unchanged in the urine via renal tubular secretion and glomerular filtration. Minor intracellular phosphorylation to active triphosphate. |
| Excretion | Renal (approximately 70% unchanged, 30% as metabolites); biliary/fecal minimal. |
| Half-life | Terminal elimination half-life is 1.0–1.6 hours in adults; intracellular active triphosphate half-life is 3.5–7 hours, supporting twice-daily dosing. |
| Protein binding | Negligible (<5%) binding to plasma proteins. |
| Volume of Distribution | 0.5–1.0 L/kg, indicating distribution into total body water. |
| Bioavailability | Oral: 86.4% (range 79–99%) in adults; high and consistent. |
| Onset of Action | Oral: Peak plasma concentration achieved in 1–1.5 hours; antiviral effect begins within 1–2 days. |
| Duration of Action | Duration of antiviral effect persists for 12–24 hours based on intracellular triphosphate levels; dosing every 12 hours maintains therapeutic effect. |
30 mg orally every 12 hours (for weight ≥60 kg: 40 mg every 12 hours)
| Dosage form | FOR SOLUTION |
| Renal impairment | CrCl >50 mL/min: no adjustment; CrCl 26-50 mL/min: 15 mg every 12 hours (≥60 kg: 20 mg every 12 hours); CrCl 10-25 mL/min: 15 mg every 24 hours (≥60 kg: 20 mg every 24 hours); CrCl <10 mL/min or hemodialysis: 15 mg every 24 hours (≥60 kg: 20 mg every 24 hours, administer after dialysis) |
| Liver impairment | Child-Pugh Class A or B: no dose adjustment; Child-Pugh Class C: reduce dose or consider alternative therapy (no specific dosing guidelines available) |
| Pediatric use | For birth to 13 days: 0.5 mg/kg/dose every 12 hours; for 14 days to <30 kg: 1 mg/kg/dose every 12 hours; for ≥30 kg: 30 mg every 12 hours (maximum 40 mg every 12 hours for weight ≥60 kg) |
| Geriatric use | Consider age-related renal impairment; monitor renal function and adjust dose accordingly; no specific dose adjustments based solely on age |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.
| Breastfeeding | Stavudine is excreted into human breast milk at concentrations approximately 0.5-2.0 times maternal plasma (M/P ratio ~0.5-2.0). However, due to the risk of HIV transmission via breastfeeding, HIV-infected mothers should not breastfeed. In non-HIV contexts, such as hepatitis B treatment, limited data exist; alternative agents with better safety profiles are preferred. The drug is considered compatible with breastfeeding in non-HIV indications, but careful monitoring of the infant for symptoms of mitochondrial toxicity (e.g., neuropathy, lactic acidosis) is recommended. |
| Teratogenic Risk | Stavudine is classified as FDA Pregnancy Category C. Animal studies have shown evidence of embryotoxicity and increased incidence of fetal skeletal variations at doses producing maternal toxicity. Human data are limited but have not shown a clear increase in major birth defects above background. There is a risk of mitochondrial toxicity in fetuses exposed in utero, potentially manifesting as neurological disorders or lactic acidosis. First trimester exposure carries theoretical risk; however, antiretroviral therapy is generally continued during pregnancy to prevent vertical transmission. The risk-benefit ratio favors use when indicated. Second and third trimester exposure: no specific teratogenic effects documented, but mitochondrial dysfunction may be exacerbated. |
■ FDA Black Box Warning
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including stavudine. Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. Co-administration of stavudine with didanosine is contraindicated because of increased risk of toxicity.
| Common Effects | Peripheral neuropathy |
| Serious Effects |
["Hypersensitivity to stavudine or any component of the formulation","Co-administration with didanosine (due to increased risk of toxicity)"]
| Precautions | ["Lactic acidosis/severe hepatomegaly with steatosis","Pancreatitis (especially in combination with didanosine)","Peripheral neuropathy","Lipodystrophy","Hepatic impairment","Renal impairment (dose adjustment required)","Immune reconstitution syndrome"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal complete blood count, hepatic function, and lactic acid levels regularly due to risk of lactic acidosis and hepatotoxicity. Assess for signs of peripheral neuropathy. Fetal monitoring includes routine prenatal ultrasound to assess growth and anatomy. In third trimester, non-stress testing or biophysical profile may be considered if there are concerns about placental insufficiency. Newborns should be monitored for signs of mitochondrial toxicity (e.g., hypotonia, seizures, respiratory distress) and have baseline and follow-up lactate levels. |
| Fertility Effects | Animal studies have shown no significant adverse effects on fertility at clinically relevant doses. In humans, stavudine has not been associated with impaired fertility. However, HIV infection itself can affect fertility, and its treatment may restore health. There is no evidence of long-term impact on male or female reproductive function. |